Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients
22.11.2022 16:00:00 EET | Business Wire | Press release
Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ReActiv8®-C study. Patients implanted with ReActiv8 at Klinikum Itzehoe were consecutively included into this cohort if they presented with back pain ≥6 and no prior lumbar surgery. The one-year results, published in World Neurosurgery, showed that a majority of the 44 patients followed up with demonstrated statistically significant improvements in pain (NRS), disability (ODI) and quality of life (EQ-5D-5L).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005230/en/
(Graphic: Business Wire)
This interim analysis indicates that the response to ReActiv8 for these patients is durable and the benefits improve over time, consistent with both a restorative mechanism of action and the ReActiv8-B randomized clinical trial results.
Dr. Med. Ardeshir Ardeshiri, Head physician of the Spine Surgery Section of the Clinic for Trauma Surgery and Orthopedics, Klinikum Itzehoe, said: “These favorable real-world data are consistent with the ReActiv8-B study, which is extremely important for me in adopting new technologies. I am excited to continue offering restorative neurostimulation with ReActiv8 for my patients with multifidus dysfunction resulting in chronic axial low back pain.”
Jason Hannon, CEO of Mainstay Medical, said: "These real-world results further validate ReActiv8’s restorative mechanism of action, which treats a primary underlying cause of mechanical chronic lower back pain, multifidus dysfunction. German physicians have been some of our foremost implanters of ReActiv8, and we look forward to continuing to make the therapy more broadly available to patients in this region.”
Link to publication of the study Real-World Evidence for Restorative Neurostimulation in Chronic Low Back Pain—a Consecutive Cohort Study - ScienceDirect
About ReActiv8®
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy, and who are not candidates for spine surgery. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US.
About Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation™ system, ReActiv8®, for people with disabling mechanical CLBP. Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.
Further information can be found at www.mainstaymedical.com .
Forward-Looking Statements
All statements in this announcement other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements may include, without limitation, statements regarding the company’s intentions, beliefs or current expectations concerning, among other things, the company’s commercial efforts and performance, financial position, financing strategies, product design and development, regulatory applications and approvals, and reimbursement arrangements.
Forward-looking statements involve risk and uncertainty and are not guarantees of future performance. Actual results may differ materially from those described in, or suggested by, the forward-looking statements. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the risks and uncertainties included in the company’s Annual Report for the year ended 31 December 2021, which should be read in conjunction with the company’s public disclosures (available on the company’s website ( www.mainstaymedical.com ). The forward-looking statements herein speak only as of the date of this announcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005230/en/
Contact information
PR and IR Enquiries:
LifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com
FTI Consulting (for Ireland)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
Email: mainstay@fticonsulting.com
Mainstay Medical
Corporate Communications
Email: Media@mainstaymedical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Defines Its Role as the Technology Behind Better Decisions in the AI Era7.4.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a renewed brand identity that reflects its role in empowering organizations to make better decisions in complex, high-stakes environments. As organizations increasingly rely on optimization to put their AI-driven insights into action, the Gurobi Optimizer is a foundational component of decision intelligence systems, where different approaches to AI—from prediction to optimization—work together to guide business outcomes. “AI has transformed how organizations generate insight, but insight alone does not drive outcomes—decisions do,” said Duke Perrucci, CEO, Gurobi. “We see optimization as the GPS for AI, enabling users to determine the best possible course of action in complex environments. Those decisions are what drive real outcomes, and we’re proud to be the technology behind them.” Across industries such as energy, supply chain management, manufacturing, and finance, organizations trust Gurobi
Poland's Galaxy Systemy Informatyczne Becomes First Private Enterprise to Buy Quantum Computer from IQM7.4.2026 16:00:00 EEST | Press release
IQM Quantum Computers, a global leader in superconducting quantum computing, today announced a commercial milestone to deploy a hybrid integrated quantum computer at GalaxySystemy Informatyczne Sp. z o.o., marking its first deployment in a private enterprise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407351934/en/ IQM Radiance quantum computer Galaxy has been implementing innovations in security, digitisation, and hardware infrastructure while providing IT solutions, supporting HPC infrastructure to shape Poland’s economy based on data and artificial intelligence. The 54-qubit Radiance system will also be the most advanced quantum computer in Poland, and Galaxy, a provider of technological solutions, will become the first private company in the world to own and operate such quantum infrastructure. The system, which will be installed at Galaxy’s headquarters in Zielona Góra in the fourth quarter of 2026, wil
Cessna SkyCourier Strengthens Mission Versatility With New In‑Flight Operable Door Option7.4.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced a new In-Flight Operable Door option for the passenger variant of its twin-engine, large-utility Cessna SkyCourier turboprop, expanding the aircraft’s Special Mission versatility for military, humanitarian and commercial operations. The functionality is expected to be available as a Special Mission factory-installed option in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407228562/en/ Mission flexibility starts at the Cessna SkyCourier door “An In-Flight Operable Door builds on the Cessna SkyCourier’s reputation for reliability and adaptability, reinforcing its role as a purpose-built solution for high-demand missions,” said Bob Gibbs, vice president, Special Missions Sales. “The option opens new opportunities for customers worldwide, including armed forces, smokejumpers, disaster relief groups and commercial skydiving operators.” The Cessna
Peruvian Army Selects Beechcraft King Air 360C for Multi-Mission Operation7.4.2026 16:00:00 EEST | Press release
The Peruvian Army has signed an agreement to purchase a cargo door equipped Beechcraft King 360C aircraft, which is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, to deliver critical services for communities across the country. With its generous payload, the twin-engine turboprop will enhance the Army’s capability to perform medical evacuations, transport patients and provide rapid humanitarian aid during disaster relief efforts. The aircraft is expected to enter service in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407176246/en/ Beechcraft King Air 360C supporting the Peruvian Army’s emergency response, medical evacuation and disaster relief missions This order follows the delivery of two multi-mission, air medical equipped Beechcraft King Air 360CHW aircraft to the Peruvian Air Force. The King Air 360CHW is cargo door equipped and fitted for operation at higher operating
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery7.4.2026 16:00:00 EEST | Press release
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities. “Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.” Enki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom